On January 11, 2021 Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) reported that it will be presenting data from MARIO-275 on the first day of the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) 2021 Genitourinary Cancers Symposium to be held virtually, February 11-13, 2021 (Press release, Infinity Pharmaceuticals, JAN 11, 2021, View Source [SID1234573798]). MARIO-275 is a randomized, placebo- controlled Phase 2 study evaluating the benefit of adding eganelisib to nivolumab (Opdivo) in platinum-refractory, I/O naïve patients with advanced urothelial cancer over nivolumab monotherapy, which is approved in this setting.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Presentation Details
Title:
Preliminary analysis of a phase II, multicenter, randomized, active-control study to evaluate the efficacy and safety of eganelisib (IPI-549) in combination with nivolumab compared to nivolumab monotherapy in patients with advanced urothelial carcinoma.
Presenter:
Piotr Tomczak M.D., Ph.D.
Date:
February 11, 2021 8:00 AM – 6:30 PM EST
Poster Session:
Urothelial Carcinoma
Abstract:
436